Benefits of a Revised Approach to Anion Exchange Flow-Through Polish Chromatography - A high-performance anion exchange resin performs well compared with membranes. In addition, the resin offers great

ADVERTISEMENT

Benefits of a Revised Approach to Anion Exchange Flow-Through Polish Chromatography
A high-performance anion exchange resin performs well compared with membranes. In addition, the resin offers greater flexibility and cost savings.


BioPharm International Supplements
Volume 24, Issue 4, pp. s16-s20

Conclusion

The novel approach of using a short, disk-like column with a resin capable of operating at high flow rates for AEX flow-through polish chromatography delivers increased flexibility when designing a purification scheme. This format is ideal for rigid resins with flow rate independent performance driven by the convective properties of the base bead. The properties of POROS HQ, for example, drive increased throughput and smaller column sizes, and ultimately a column that can be sized based on capacity for impurities. In addition, POROS HQ has been shown to have high impurity binding capacity and clearance over a range of process conditions, including high conductivity conditions (data not shown). This decreases the need for dilution of the feed stream or inclusion of a diafiltration step prior to loading on the HQ column, making the process more efficient and cost-effective. If disposability is a factor, Life Technologies now offers Go-Pure Pre-Packed Chromatography Columns for maximum convenience, providing faster time to process and faster time between processes.

This new approach to AEX FT polish chromatography increases process development flexibility and offers a more cost effective approach to this process step as compared to improperly, oversized soft gel columns, and membranes with limited sizes and expensive formats at larger scale. This study shows that a high performance AEX resin competes well with the performance of membranes, providing similar processing times and the added benefits of reusability, which decreases material costs with increased cycles as modeled in Table 4. In addition, ease of packing at different scales in various column formats and the ability to implement initial process design from early phase manufacturing to commercial manufacturing reduces overall process development costs and decreases time to market.

For Research Use Only. Not intended for animal or human therapeutic or diagnostic use.

Acknowledgments

The authors would like to thank Susanne Alexander, Roger Decker, and Elliot Haimes for assistance with the execution of these studies.

SHELLY COTE PARRA, MS, is a senior field applications scientist in the POROS Applications group at Life Technologies,
. CHRISTINE GEBSKI, MS, is the director of POROS R&D and Applications at Life Technologies, Bedford, MA,
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here